ºÚÁϳԹÏÍø

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • ºÚÁϳԹÏÍø News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Jul 22 2020

Full Issue

We Won't Skimp On Safety, Vaccine Makers Promise Lawmakers

In testimony to Congress, officials from AstraZeneca, Johnson & Johnson, Merck, Moderna and Pfizer said the unprecedented speedy push for a vaccine won't cause them to cut corners.

The pharmaceutical industry does not want you to worry about the safety or efficacy of a future Covid-19 vaccine. Officials from five major vaccine makers — AstraZeneca, Johnson & Johnson, Merck, Moderna, and Pfizer — all used their testimony before a House investigative subcommittee on Tuesday to push back on concerns that the Food and Drug Administration might prematurely approve a vaccine for the novel coronavirus and thereby put Americans at risk. (Garde, 7/21)

Companies behind leading coronavirus vaccine candidates told lawmakers Tuesday they're not worried that political pressure will lower standards for approval of any eventual shot — but they need the government to decide who gets it first. President Donald Trump has repeatedly promised a vaccine by the end of the year, raising concerns that his administration will rush to approve one without adequate proof that it works. (Owermohle, 7/21)

Drug company executives sought to reassure House Democrats that the federal government is not lowering its approval standards, and any coronavirus vaccine that gains approval will be safe. Executives from Moderna, Janssen, Merck, AstraZeneca and Pfizer told lawmakers during an Energy and Commerce subcommittee hearing Tuesday that despite the unprecedented speed, any vaccine candidate will be safe. (Weixel, 7/21)

Representatives of five companies developing coronavirus vaccines testified before a House panel Tuesday about their quest to produce shots in record time — and distribute them worldwide. Pharmaceutical executives’ appearances on the Hill in recent years have almost entirely been tied to the heated debate over high drug costs, from soaring insulin prices to patent games that limit generic competition. (Owermohle, 7/21)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • ºÚÁϳԹÏÍø
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF